Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
A cohort study on the risk of major adverse kidney events for new patients initiated on empagliflozin versus other non-SGLT2I antihyperglycemics.
Read More »Empagliflozin Effect on Major Adverse Kidney Events
The Effect of Dapagliflozin on Renal Disease Progression
There is a potential role in using dapagliflozin in patients with CKD.
Read More »Empagliflozin Outcome on Obstructive Sleep Apnea, Cardiovascular, and Renal Events
The unique benefits of using empagliflozin need to be considered when determining treatments for type 2 patients.
Read More »Sotagliflozin: Implications in Patients Living With Chronic Kidney Disease
A new phase 3 study on novel SGLT inhibitor shows favorable results in those living with severe renal impairment.
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »Another Oral Combination Antidiabetic Agent
Dual and triple therapy just got a little easier.
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes
Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?
Read More »Amputations are No Longer Listed As a Box Warning For Canagliflozin
The risk for leg and foot amputation is now listed under Warnings and Precautions instead of box warning.
Read More »SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Cardiovascular events decline for patients using which antidiabetic medication?
Read More »